Clay Siegall, PhD, is the co-founder, President and CEO of Seattle Genetics, a biotechnology firm that develops antibody-based therapies primarily for cancer and other critical illnesses. Seattle Genetics is the leading biotech company in Washington with a market value of approximately $10 billion. The company has 900 employees. Clay Siegall has built the firm on a solid foundation of vigorous research and marketing. He also plans to expand its staff base with an addition of 200 more employees. Seattle Genetics’ flagship drug, ADCETRIS, which treats Hodgkin lymphoma, is undergoes expansive tests before it is sold. Seattle Genetics’ capabilities are beyond drug development. They have the expertise to navigate complexities of international marketing, including selling international commercial rights to Takeda Pharmaceuticals.
Siegall’s ambition to succeed in the global market was demonstrated when he spent $2 billion to purchase worldwide rights to sell a cancer drug developed by Immunomedics. Other achievements made by Dr. Clay Siegall include the FDA approval of Adcetris. Siegall is overseeing the development of 11 drugs where four have high chances of generating more returns. In 2016, Seattle Genetics made sales worth $418 million, an increase of 46 percent from 2014. Its stock price has also tripled from $20 to $66. They have also intensified their research by increasing the expenditure by 64 percent from 2014 to $376 million in 2016.
About Clay Siegall
Clay Siegall, PhD, ventured into the field of cancer therapy after a firsthand experience of losing his close family member to cancer. This process made him aware of the insufficient oncology tools at that time. To this end, he co-founded Seattle Genetics in 1998 with the goal of improving the lives of cancer patients. For 30 years, Clay Siegall has worked relentlessly to deliver cancer therapies that enhance thee lives of cancer patients. He is a graduate of the University of Maryland where he graduated with a B.S. in zoology. Later, he joined George Washington University to pursue his PhD in genetics.
At the initial stage of his career, Dr. Clay Siegall spent many years working with Bristol-Myers Squibb Pharmaceutical Research Institute before joining the National Cancer Institute. He sits on the boards of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. Clay’s excellent work in biotechnology has been rewarded severally, including receiving the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. In 2013, the accomplished scientist was named the University of Maryland Alumnus of the Year for Computer, Math, and Natural Sciences. He has published more than 70 works.